Navigation Links
Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
Date:5/5/2010

drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.  

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application submission in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  In February 2010, Alexza established a partnership with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 in the U.S. and Canada.    

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.  

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial.  Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia.  More information, including this and past press releases from Alexza, is available online at www.alexza.co
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
2. Alexza Pharmaceuticals Files Shelf Registration Statement
3. Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
4. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
5. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
6. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
7. Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
8. Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
9. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
10. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
11. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... -- Hill-Rom (NYSE: HRC ) today announced a ... WA ), the nation,s third largest not-for-profit health ... as Hill-Rom now becomes Providence Health,s sole-source provider of ... surface products. Providence Health is one ... operates 34 hospitals, 475 physician clinics, 22 long-term care ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... , Sept. 23, 2014   COTA, Inc. ... planned $7 million Series A funding round led by ... COTA is the first big data platform designed by ... cost analysis for cancer care in support of healthcare,s ... used to expand development of the COTA platform, hire ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... March, 9, 2007-Active Biotech (ACTI.ST), today,announced new positive clinical ... treatment of prostate cancer. , By step-wise dose escalation, ... which corresponds to a doubling of the previously,reported maximum ... a step-wise intra-patient dose-escalation enables a dose,of 1 mg/day ...
... DENVER--(BUSINESS WIRE)--Mar 12, 2007 - Ceragenix Pharmaceuticals,Inc. ... and dermatology, today announced that a catheter,treated ... biofilm,formation in a 21 day study., In ... soaked daily in a phosphate-suffered solution along ...
Cached Medicine Technology:Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
(Date:9/23/2014)... 2014 Avid collector Andrew Hawley, from Vintage ... Eagle Auditorium Seattle concert posters. The Doors were a smash ... that year. The Seattle Eagles Auditorium concert was held on ... return to Eagles Auditorium in November the same year. The ... and comes in three colors. The poster is a split ...
(Date:9/23/2014)... 2014 What: Rutgers Presbyterian Church, ... Side that embodies the inclusion and diversity of ... and the Ecological Crisis, a public lecture led ... Emerita of Old Testament at Louisville Presbyterian Seminary. ... that lends insight into current ecological problems, including ...
(Date:9/23/2014)... Oregon survey about an exercise DVD that adds short ... elementary school students found it had a high level ... clear advantages for overly sedentary educational programs. , Called ... the Healthy Youth Program of the Linus Pauling Institute ... Brain Breaks leads children in 5-7 minute segments of ...
(Date:9/23/2014)... (September 23, 2014) Both patients and healthcare ... computed tomography (CT) colonography greatly outweighs the potential ... precipitated by false-positive diagnoses, according to a new ... journal Radiology . , Diagnostic tests used ... organ. However, when screening for colorectal cancer with ...
(Date:9/23/2014)... September 23, 2014 The ... rhinitis (AR) is highly fragmented, with the ... formulations available, under different regulatory restrictions, with ... Europe has the most developed market, with ... allergen immunotherapy tablets (AITs) all being available. ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... Increase for Small Business Owners at ... http://www.bluecrossca.com/click4biz , THOUSAND OAKS, Calif., ... fastest growing segments of California,s economy, however,many small business owners ... Blue Cross of California has just made it,easier for small ...
... vitamins and minerals does not seem to prevent the degenerative ... study published on bmj.com today. , Age related ... older people. It is caused by the progressive break down ... centre of the retina at the back of the eye. ...
... 8 Proposed,regulations that would govern who owns ... grants to for-profit organizations fail,to ensure affordable access ... for the research, the Foundation for Taxpayer and ... the people who have paid for the research ...
... Saturn, committed to health, fitness,and healthy living in communities ... health and fitness expo, held in conjunction with the ... Saturn Health and Fitness Expo, which runs Oct. 19-20 ... vendors,informational booths and groups that provide services to runners. ...
... 8 - The Washington,State Veterinary Medical Association awarded ... veterinarian with Olympia Pet,Emergency in Lacey. (Logo: ... his award in recognition of his dedication to,organized ... Washington,State University,s College of Veterinary Medicine, he has ...
... Help ... Owners Cope, SACRAMENTO, Calif., Oct. ... and language skills died last,month, his owner, scientist Irene Pepperberg, needed time ... it. Newspapers and web,sites printed his obituary and many people sent condolences. ...
Cached Medicine News:Health News:New Online Tool Makes Enrollment in Blue Cross of California Easier 2Health News:Antioxidants do not prevent degenerative eye disease 2Health News:Revised California Stem Cell Research Rules Fail to Ensure Affordable Access to Cures, Consumers Warn 2Health News:Saturn Shows Its Commitment to Health and Fitness by Becoming Expo Title Sponsor for The Detroit Free Press/Flagstar Marathon 2Health News:Lacey Veterinarian Awarded 2007 WSVMA Recent Graduate Award 2Health News:We Love Our Pets and Grieve When They Die 2Health News:We Love Our Pets and Grieve When They Die 3
... Retinol binding Proetin (RBP) is small ... a complex with pre-albumin in blood but ... has been deliverd to the target cells. ... at the glomerulus and catabolized in the,renal ...
... is an enzyme immunoassay (EIA) kit for ... of the subclass of Anti-Neutrophil Cytoplasmic Antibodies ... as an aid in the diagnosis of ... associated with vasculitic disorders and glomerulonephritis (GN). ...
Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-96 Myeloperoxidase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
Medicine Products: